WO2024005422A1 - Variants de b7-h6 à affinité de liaison améliorée pour nkp30 - Google Patents

Variants de b7-h6 à affinité de liaison améliorée pour nkp30 Download PDF

Info

Publication number
WO2024005422A1
WO2024005422A1 PCT/KR2023/008393 KR2023008393W WO2024005422A1 WO 2024005422 A1 WO2024005422 A1 WO 2024005422A1 KR 2023008393 W KR2023008393 W KR 2023008393W WO 2024005422 A1 WO2024005422 A1 WO 2024005422A1
Authority
WO
WIPO (PCT)
Prior art keywords
variant
amino acid
nkp30
binding affinity
acid substitutions
Prior art date
Application number
PCT/KR2023/008393
Other languages
English (en)
Korean (ko)
Inventor
정상택
김보미
하지연
Original Assignee
고려대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교 산학협력단 filed Critical 고려대학교 산학협력단
Publication of WO2024005422A1 publication Critical patent/WO2024005422A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La présente invention concerne des variants de B7-H6 ayant une affinité de liaison améliorée pour NKp30. Les variants de B7-H6 selon la présente invention peuvent augmenter l'activation de cellules tueuses naturelles (NK) en raison d'une affinité de liaison significativement accrue pour NKp30, qui est un récepteur d'activation de cellules NK, par comparaison avec le type sauvage, sont faciles à pénétrer dans le micro-environnement tumoral en raison d'une taille beaucoup plus petite que les anticorps, et sont facilement produits, et peuvent ainsi être utilisés de manière efficace seuls ou en combinaison avec divers agents immunothérapeutiques pour traiter le cancer ou des maladies infectieuses.
PCT/KR2023/008393 2022-06-29 2023-06-16 Variants de b7-h6 à affinité de liaison améliorée pour nkp30 WO2024005422A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0079826 2022-06-29
KR20220079826 2022-06-29

Publications (1)

Publication Number Publication Date
WO2024005422A1 true WO2024005422A1 (fr) 2024-01-04

Family

ID=89380778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/008393 WO2024005422A1 (fr) 2022-06-29 2023-06-16 Variants de b7-h6 à affinité de liaison améliorée pour nkp30

Country Status (2)

Country Link
KR (1) KR20240003756A (fr)
WO (1) WO2024005422A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091950A (ko) * 2007-10-04 2010-08-19 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
WO2011070443A1 (fr) * 2009-12-09 2011-06-16 Institut National De La Sante Et De La Recherche Medicale Anticorps monoclonaux qui se lient à b7h6 et leurs utilisations
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091950A (ko) * 2007-10-04 2010-08-19 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
WO2011070443A1 (fr) * 2009-12-09 2011-06-16 Institut National De La Sante Et De La Recherche Medicale Anticorps monoclonaux qui se lient à b7h6 et leurs utilisations
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein 19 March 2015 (2015-03-19), ANONYMOUS : "B7H6, partial [synthetic construct]", XP093121937, retrieved from NCBI Database accession no. AIC53717.1 *
M. G. JOYCE, TRAN P., ZHURAVLEVA M. A., JAW J., COLONNA M., SUN P. D.: "Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 15, 12 April 2011 (2011-04-12), pages 6223 - 6228, XP055043601, ISSN: 00278424, DOI: 10.1073/pnas.1100622108 *
SKOŘEPA ONDŘEJ, PAZICKY SAMUEL, KALOUSKOVÁ BARBORA, BLÁHA JAN, ABREU CELESTE, JEČMEN TOMÁŠ, ROSŮLEK MICHAL, FISH ALEXANDER, SEDIVY: "Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation", CANCERS, CH, vol. 12, no. 7, 21 July 2020 (2020-07-21), CH , pages 1998, XP093121934, ISSN: 2072-6694, DOI: 10.3390/cancers12071998 *

Also Published As

Publication number Publication date
KR20240003756A (ko) 2024-01-09

Similar Documents

Publication Publication Date Title
JP7307919B2 (ja) インターロイキン－２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
Monach et al. A unique tumor antigen produced by a single amino acid substitution
Srivastava et al. Individually distinct transplantation antigens of chemically induced mouse tumors
Palladino Jr et al. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas
EP1124568B1 (fr) Molecules de liaison polyspecifiques et leurs utilisations
CN106755107B (zh) 一种car新分子及其在肿瘤治疗中的应用
JP2023542417A (ja) Ｋｒａｓ変異に特異的ｔ細胞受容体のスクリーニング及び抗腫瘍用途
WO2000058480A1 (fr) Nouvelle cytidine desaminase
JPH08500837A (ja) Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
JPH03501330A (ja) カケクチンと反応するモノクロナール抗体
JP5934897B2 (ja) Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
CA2404233A1 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
JP4900884B2 (ja) 腫瘍抗原
JP2000154153A (ja) 多段カスケ―ド型追加免疫ワクチン
TW201930360A (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
WO2021043229A1 (fr) Protéine de fusion bifonctionnelle recombinée ciblant une tumeur et son utilisation
JPH06507384A (ja) 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
WO1998022510A9 (fr) Procedes de production d'anticorps monoclonaux de poulet
GB2603166A (en) Therapeutic and Diagnostic Agents and Uses Thereof
WO2022098084A1 (fr) Anticorps de liaison au récepteur fc alpha
CA2130173A1 (fr) Anticorps produits par genie genetique
WO2024005422A1 (fr) Variants de b7-h6 à affinité de liaison améliorée pour nkp30
JP2016523264A (ja) Ｔｏｓｏに対する抗体
WO2022220603A1 (fr) Anticorps humain ciblant le virus de covid-19
JP2021526013A (ja) 抗ヒトｌａｇ−３モノクローナル抗体とその応用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23831782

Country of ref document: EP

Kind code of ref document: A1